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Abstract: Breast cancer (BC) is the second leading cause of death among Mexican women 
over 40 years of age. This study aimed to identify and examine the effects of cancer stage and 
surgical treatment on the quality of life (QOL) of Mexican women with early stage breast cancer 
(ESBC) treated with either modiﬁ  ed radical mastectomy (MRM) or breast conservative surgery 
(BCS), plus adjuvant chemotherapy. The QLQ-C30 and QLQ BR-23 questionnaires were used to 
assess QOL. Sociodemographic characteristics and clinical factors of 102 women with early BC 
were also evaluated; analysis of variance (ANOVA) was performed and a statistical signiﬁ  cance 
of p   0.05 was assumed. Most women were of reproductive age. Meaningful differences in 
QOL as a result of surgical treatment, in women receiving BCS compared with those receiving 
MRM, were limited to body image. We conclude that MRM and BCS are essentially equivalent 
choices in terms of QOL, with the exception of the impact on body image. In general, women 
who received BCS had a better perceived QOL.
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Introduction
Breast cancer (BC) is the leading cause of cancer death among women around the 
world.1,2 BC and cervicouterine cancer are the most common cancers in Mexican 
women.3 BC is the second leading cause of death among Mexican women aged 40 or 
more, killing approximately 10 women daily; an average of one death every two and 
a half hours.4
The ﬁ  rst step in combatting cancer is making the diagnosis. This requires a 
combination of careful clinical evaluation and diagnostic tests, which may include 
endoscopy, imaging, histopathology, cytology, and laboratory tests.3 Once the diagnosis 
is conﬁ  rmed, the cancer is staged. A decision on therapy is made and an experimental 
treatment protocol established.5
For the majority of patients diagnosed with early stage breast cancer (ESBC), the 
options for local treatment are mastectomy or breast conservative surgery (BCS) with 
radiotherapy.6,7
The objectives of BC treatment are eradication of the cancer, prolongation of 
life, and improved quality of life. The diagnosis of breast cancer and its subsequent 
treatment have been shown to have a signiﬁ  cant inﬂ  uence on a woman’s physical 
functioning, mental health, and well-being, causing substantial disruption to her 
quality of life (QOL).1,6,8,9
A feature common to all forms of cancer is the failure of the mechanisms which 
normally regulate cell growth, proliferation, and death. The resulting tumor, which 
begins as a small anomaly, becomes larger and more injurious, invades neighboring 
cells, and is eventually propagated in other parts of the body.10ClinicoEconomics and Outcomes Research 2009:1 2
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Measures of health-related quality of life (HRQOL) are 
becoming increasingly important in assessing the effects of 
chronic illness, and the medical interventions designed to 
treat them. National spending on medical care is growing 
rapidly in every country.2,11 HRQOL measures could enhance 
our understanding of health status in any given country, and 
promote further study of the economic causes and effects of 
changes in health status.2
HRQOL is a multidimensional construct that represents 
the patient’s perception of the effects of an illness and its 
associated therapy on his or her day-to-day functioning.12 
Once active treatment is completed, some women celebrate; 
others become anxious about recurrence and feel that they 
have lost a proactive shield against cancer.13 Many studies 
report persistent disturbances in family functioning because 
marital issues were ignored during the cancer treatment 
phase. Body image and age, especially after mastectomy, 
have also been detected as concerns.14,15
In Mexico, very little (if any) research has compared 
the HRQOL of women treated with modiﬁ  ed radical mas-
tectomy (MRM), with the HRQOL of women experiencing 
BCS. Factors such as patient education, spouse support and 
employment status, ﬁ  nancial stability, and disease stage, 
have been found to inﬂ  uence not only quantity of survival, 
but also HRQOL.1 To enhance the QOL for Mexican women 
with BC, more QOL studies to investigate the effect of socio-
demographic and clinical factors on their QOL are needed.
The objectives of the present study were to identify and 
examine the relationship between cancer stage and surgical 
treatment with the QOL of two groups of Mexican women 
with ESBC, who had been treated with MRM or BCS plus 
adjuvant chemotherapy at La Raza, a large public hospital in 
Mexico City with specialized breast cancer services.
Materials and methods
Study design and sample selection
A prospective, descriptive and analytical study was 
conducted. The study population consisted of women diag-
nosed with ESBC (stages I or II). Mexican epidemiological 
sources show that most women diagnosed with BC are older 
than 35 years.3,10 Consequently, eligibility criteria included: 
a) age  35 years and  65 years; b) a primary diagnosis of 
BC treated with a surgical procedure (BCS or MRM); c) an 
existing medical record at La Raza hospital before the start of 
the study, and attending this hospital as an outpatient for che-
motherapy treatment during the study period; and d) capable 
of completing the European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire version 3 
(EORT QLQ-C30), and the Breast Cancer-Speciﬁ  c Quality 
of Life Questionnaire (QLQ BR-23).16,17 Both QOL question-
naires were translated into Spanish and validated in Mexico 
by the EORT Quality of Life Group and have been tested 
for validity in various populations.18 The EORT Quality of 
Life Group granted written permission to the ﬁ  rst author of 
the study.
Participants provided written consent, and approval was 
granted by the La Raza Hospital Health Service Research 
and Ethics Committee.
The initial sample screening was completed with all the 
medical records of women with cancer in the study period. 
Most women in the preliminary sample (506) did not meet 
the inclusion criteria, that is, they were older than 35 years, 
had an advanced stage of BC (III and IV), or/were suffering 
from other types of cancer. Consequently, only 102 women 
of a total of 506 women with medical records were included 
in the present study. The questionnaires were applied only 
once during the study period (which lasted from September 
to November 2007).
Data collection and study measures
Information about treatment and clinical factors was obtained 
from patient medical records. BC stage was classiﬁ  ed using 
the American Joint Committee on Cancer (AJCC) TNM 
Staging System for Breast Cancer. A 17-item questionnaire 
was applied to the study population sample (102 women 
with BC in stages I–II). Questionnaire items included 
sociodemographic characteristics (age, level of education, 
marital status, employment status) and clinical factors (breast 
cancer stage and treatment). Clinical factor responses were 
conﬁ  rmed from patient medical records. QOL was measured 
by self-completed questionnaires.
Quality of life questionnaire
QOL was assessed by patient responses to a generic cancer 
instrument, the QLQ-C30 and QLQ BR-23, as mentioned 
above.
Scoring of QLQ-C30 and QLQ-BR23
The QLQ-C30 contains 30 questions and has been grouped 
by the instrument’s authors into three scales: one global 
QOL scale (two items), ﬁ  ve function scales (15 items) and 
nine symptom scales (13 items). Scale scores are the average 
of the component item responses, transformed linearly to a 
range of 0–100 (as described in the User’s Guide).19 The 
QLQ-BR23 comprises 23 questions and has been grouped 
by the instrument’s author into two scales: four function ClinicoEconomics and Outcomes Research 2009:1 3
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scales (13 items) and four symptom scales (eight items). 
Scale scores are transformed linearly to a range of 0–100. 
For both QOL questionnaires (QLQ-C30 and QLQ-BR23) 
the function scales and the global QOL scale, a higher score 
corresponds to a better QOL. For the symptom scales, a 
higher score indicates more frequent and/or intense symptom 
experience and thus a lower QOL.20
Statistical analysis
Each QOL measure was standardized to a score ranging from 
0 to 100 by using the linear transformation in the EORTC 
QLQ Scoring Manual. Bivariate associations between stage 
and treatment and each of the QOL measures were inves-
tigated using analysis of variance (ANOVA). A statistical 
signiﬁ  cance of p   0.05 was assumed. All analyses were 
performed using SPSS version 13 (SPSS Inc., Chicago, IL).
Results
Table 1 shows the study population categorized by sample 
characteristics and by primary surgical treatment. 102 women 
with BC in stages I–II were included; 44 (43.1%) subjects 
were aged 56 to 65; 32 (31.4%) subjects were aged 46 to 55. 
Most respondents, that is, 60 (58.8%), had completed elemen-
tary school, 24 (23.5%) middle school, 13 (12.74%) techni-
cal studies and only 5 (4.9%) had reached a post-secondary 
degree. 65 (63.4%) were homemakers and 23 (22.54%) 
were formally employed. Three (2.94%) were self-employed 
(Table 1). Ninety-three subjects (91.17%) were in stage II 
and 9 (8.82%) were in stage I (Table 1).
Eighty-four (82.4%) women received MRM and only 
18 (17.6%) BCS. In relation to treatments (chemotherapy), 
86 (84.31%) women who had MRM were treated with 
5-ﬂ  uorouracil (5-FU), epirubicin, and cyclophosphamide 
(FEC). Of the BCS patients, 15 (14.6%) were treated with 
cyclophosphamide, methotrexate, 5-ﬂ  uorouracil (CMF), 
and one (0.98%) with other treatment agents. All subjects 
completed six cycles of chemotherapy during the study 
period (Table 1).
Sixty-eight (66.7%) women were currently married or 
had a domestic partner and 34 (33.3%) were single.
Table 1 Sample characteristics of the study population overall and by primary surgical treatment (N = 102)
Characteristics N 102 Overall (%) MRM N = 84 (%) Breast-conserving 
surgery N = 18 (%)
p-value 
(ANOVA)
Sociodemographic
Age
   35  45 26 25.5 23.1 38.8 0.272
   46  55 32 31.4 30.4 38.8 0.392
   56  65 44 43.1 48.7 22.2 0.026*
Education level
 Elementary  school 60 58.8 60.7 50 0.031*
 Junior  high 24 23.5 23.8 22.2 0.342
 Technical 13 12.74 13.09 11.1 0.605
 Bachelor  degree 5 4.9 2.38 16.6 0.571
Occupation
 Unemployed 11 10.78 8.3 22.2 0.043*
 Housekeeper 65 63.72 67.8 44.4 0.037*
 Employee 23 22.54 22.6 22.2 0.272
 Self-employed 3 2.94 1.19 11.1 0.041
Clinical factors
 Stage  I 9 8.82 3.65 33.3 0.036*
 Stage  II 93 91.17 96.34 66.6 0.021*
Treatment
 FEC 86 84.31 84.5 83.3 0.562
 CMF 15 14.70 14.2 16.6 0.813
 Others 1 0.98 1.19 0 0.260
Note: *P   0.05 statistical signiﬁ  cance.
Abbreviations: ANOVA, analysis of variance; CMF, cyclophosphamide, methotrexate, 5-ﬂ  uorouracil; FEC, 5-ﬂ  uorouracil, epirubicin, and cyclophosphamide; MRM, modiﬁ  ed 
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Tables 2 and 3 show the results of the QOL questionnaires. 
As mentioned in the methodological section (scoring QLQ-C30 
and QLQ-BR23), for both QOL questionnaires (QLQ-C30 and 
QLQ-BR23), the function scales and the global QOL scale, a 
higher score corresponds to a better QOL; for the symptom 
scales, a higher score indicates more frequent and/or intense 
symptom experience and thus a lower QOL.20
Table 2 shows the QLQ-C30 results. No significant 
difference in global state of health was observed between the 
two groups (p   0.05). Physical function was signiﬁ  cantly 
different between women treated with MRM and women 
treated with conservative surgery (p   0.05). On the symptom 
scale, the items with signiﬁ  cant differences between the two 
groups were nausea and vomiting (p   0.05).
Table 2 also shows that women who had conservative 
surgery had a higher level than women with MRM in three 
out of ﬁ  ve of the function scales. The two exceptions were 
emotional function (72.22 vs 66.20) and cognitive function 
(87.10 vs 78.70).
Table 3 shows the results of the BC-speciﬁ  c QLQ-BR23 
questionnaire by type of surgery. As a result of the variance 
analysis (ANOVA), a significant difference can be seen 
between the MRM group and the BCS group on the function, 
body image, and future perspective scales (p   0.05). The con-
servative surgery group scored considerably higher on health 
and function (87.03 vs 19.41 and 72.22 vs 29.76, respectively). 
The results show a better QOL for the BCS group than for the 
MRM accordingly to the scoring method already described.
All items on the symptom scale were significantly 
different in the two groups except for concern about hair 
loss (p   0.05).
Discussion
The age distributions of both groups (MRM and conser-
vative surgery) are consistent with those found in other 
countries.12,21
Women who had completed only elementary school 
received MRM, suggesting that education plays an important 
role in the early detection of BC.6,12,21 A lower level of educa-
tion may also be related to patient willingness to follow physi-
cian suggestions to have MRM, rather than request BCS.
Most of the women were homemakers or unemployed. Our 
results differ from those of published studies from other geo-
graphical areas, where most subjects were employed.6,12,21
The results of the present investigation provide insights 
on the effects of early stage breast cancer and its treatment 
on QOL. These ﬁ  ndings support those of studies conducted 
in other populations which suggest that patient physical-
psychological concerns, such as insomnia and lack of appetite, 
are similar regardless of the stage or type of surgery.6,12,21
Table 2 Results of the QLQ-C30 questionnaire by primary surgery
Name Scale MRM N = 84 BCS N = 18 ANOVA p value
Global health status QL 67.65 72.22 0.181
Functional scales
Physical functioning PF 86.34 91.85 0.036*
Role functioning RF 72.22 76.85 0.312
Emotional functioning EF 72.22 66.20 0.260
Cognitive functioning CF 87.10 78.70 0.073
Social functioning SF 79.56 79.63 0.991
Symptom scales
Fatigue FA 25.26 22.83 0.577
Nausea and vomiting NV 17.06 6.48 0.043*
Pain PA 24.99 16.66 0.056
Dyspnea DY 9.52 7.40 0.605
Insomnia SL 15.07 20.36 0.365
Appetite loss AP 10.71 9.25 0.805
Constipation CO 13.49 16.66 0.557
Diarrhea DI 4.36 7.4 0.392
Financial difﬁ  culties FI 39.28 27.77 0.128
Note: *P   0.05 statistical signiﬁ  cance.
Abbreviations: ANOVA, analysis of variance; BCS, breast cancer surgery; MRM, modiﬁ  ed radical mastectomy; QLQ-C30, European Organization for Research and Treatment 
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Table 3 Results of the QLQ-BR23 questionnaire by primary surgery
Name Scale MRM N = 84 BCS N = 18 ANOVA P value
Functional scales
Body image BRI 19.41 87.03 0.0285*
Future perspective BRFU 29.76 72.22 0.0371*
Symptom scales
Systemic therapy 
side effects
BEST 40.93 28.04 0.0133*
Breast symptoms BROS 54.76 8.79 0.001*
Arm symptoms BRAS 44.44 9.87 0.009*
Upset by hair loss BRHL 86.11 90.74 0.278
Note: *P   0.05 statistical signiﬁ  cance.
Abbreviations: ANOVA, analysis of variance; BCS, breast cancer surgery; MRM, modiﬁ  ed radical mastectomy; QLQ BR-23, Breast Cancer-Speciﬁ  c Quality of Life Questionnaire.
The results of the QLQ-C30 questionnaire by type of 
surgery (Table 2) show that the majority of parameters 
assessed (excepting physical function, and nausea and 
vomiting) were not signiﬁ  cantly different between women 
treated with MRM and women treated with conservative 
surgery. Women in the BCS group showed higher values on 
the global health scale (72.22), indicating a relatively better 
QOL, than those who received MRM (67.65).
The results may indicate that mastectomy does not itself 
substantially reduce QOL, compared with conservative 
surgery, apart from nausea and vomiting (17.06 versus 6.48 
in women treated with BCS) (p   0.05).6,12
The BCS group showed higher values on the function 
scales than the MRM group in all dimensions except emo-
tional function (72.22 vs 66.20).
As noted above, the only signiﬁ  cant result when comparing 
symptoms between the two groups was nausea and vomiting 
(p   0.05). The symptom scale indicates the health problems 
experienced by the patients: in this study, of the nine symptoms 
assessed, six were higher in the MRM group (indicating poorer 
QOL) than in the BCS group. Once again a slight tendency 
was shown for women treated with conservative surgery to 
present fewer health problems (symptom scales lower values) 
and hence a “better” QOL.
The results by surgery type from the QLQ-BR23 ques-
tionnaire, designed to measure QOL in women with BC, 
were consistent with other studies which also reported that 
the only signiﬁ  cant difference between the two groups (BCS 
or MRM) was body image.6,12
The BCS group showed lower levels on the symptom 
scale than the MRM group, consequently reporting fewer 
health problems, with the exception of hair loss. This result 
is consistent with other studies, in which similar results have 
been reported.6,12,21
In general, women receiving BCS perceive a better QOL 
than women treated with MRM, with the exception of hair loss, 
in which both groups showed a similar level of concern.
Study limitations
Results of the present investigation are limited by the small 
sample size and by the cross-sectional design. The effects 
of chemotherapy on QOL were not investigated because 
both groups used similar drug treatments. No radiotherapy 
equipment was available at the study site. We acknowledge 
that future investigations should also address the effect of 
chemotherapy and/or radiotherapy on QOL.
Our research group is small and independent; no grant 
or ﬁ  nancial support was received to conduct the present 
investigation. A larger sample with more sociodemographic 
and clinical variables would need extra economic and human 
resources. Our results are preliminary and not conclusive.
Conclusion
In the study sample, MRM and BCS are essentially equivalent 
choices in terms of QOL with the exception of impact on body 
image. In general, women who received BCS had a better 
QOL perception than those treated with MRM, although the 
differences were not statistically signiﬁ  cant.
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